Follicular thyroid carcinomas (FTC) arise through oncogenic pathways distinct from those involved in the papillary histotype. Recently, a t(2;3)(q13;p25) rearrangement, which juxtaposes the thyroid transcription factor PAX8 to the peroxisome proliferator-activated receptor (PPAR) ␥1, was described in FTCs. In this report, we describe gene expression in 11 normal tissues, 4 adenomas, and 8 FTCs, with or without the PAX8-PPAR␥1 translocation, using custom 60-mer oligonucleotide microarrays. Follicular cell-derived thyroid tumors include benign adenomas, papillary and follicular carcinomas, two entities considered as differentiated carcinomas, and anaplastic carcinomas. Although clinically benign thyroid nodules are common in the general population, thyroid carcinomas are infrequent tumors, and both the putative relationships between adenomas and carcinomas and the mechanisms of thyroid oncogenesis are not clearly understood.
Follicular cell-derived thyroid tumors include benign adenomas, papillary and follicular carcinomas, two entities considered as differentiated carcinomas, and anaplastic carcinomas. Although clinically benign thyroid nodules are common in the general population, thyroid carcinomas are infrequent tumors, and both the putative relationships between adenomas and carcinomas and the mechanisms of thyroid oncogenesis are not clearly understood. 1 In thyroid tumors, genetic abnormalities have been largely substantiated. Fusion of the tyrosine-kinase domain of the RET gene and the 5Ј domain of various genes (RET/PTC) and activating mutation of the B type Raf kinase (BRAF) gene constitute the two major independent and nonoverlapping genetic alterations detected in papillary carcinomas. 2, 3 A high prevalence of activating mutations of all three RAS genes has been reported in follicular neoplasms. 4 Chromosomal imbalances are also frequent in FTCs; 5 and the t(2;3)(q13;p25) rearrangement, yielding a PAX8-PPAR␥1 fusion gene, is found in 10 to 63% FTCs, 6 but also in some follicular adenomas. [7] [8] [9] These observations suggest that FTC proceeds from at least two distinct oncogenic events, namely RAS mutations and PAX8-PPAR␥1 rearrangement.
PPAR␥ in the development of tumors, including thyroid carcinomas, is still debated. 12, 13 The anti-proliferative effects of PPAR␥ agonists have been demonstrated in thyroid carcinoma cell lines 14, 15 and either induce cell-cycle arrest or promote cell-death. Furthermore, thyroid tumors not harboring PAX8-PPAR␥ translocation displayed decreased PPAR␥ gene expression, 16 -18 and this suggests that decreased activity of PPAR␥ might contribute to carcinogenesis. In FTCs, the PAX8-PPAR␥1 fusion oncogene appears to act through a dominant-negative effect on the transcriptional activity of wild-type PPAR␥1, inhibiting agonist-induced transactivation. 6 Recently, in vitro experiments demonstrated that the fusion oncoprotein contributes to the malignant transformation by acting on several pathways, some of which are normally regulated by PPAR␥. 19 To explore the physiopathological mechanisms associated to the presence of the PAX8-PPAR␥1 rearrangement, we analyzed gene profiles of normal thyroid tissues, follicular adenomas and follicular thyroid carcinomas using custom-designed 60-mer oligonucleotides microarrays of 22,000 features, representing about 17,000 distinct genes. Transcriptional changes associated with the presence or the absence of the PAX8-PPAR␥1 rearrangement revealed a 93-gene discriminating pattern. Changes in the expression of several genes of this molecular signature were confirmed by real-time quantitative real-time polymerase chain reaction (Q RT-PCR) in a large series of thyroid tissues and at the protein level, by immunohistochemistry on a tissue array.
Materials and Methods

Tissue Samples
Sixty-five thyroid tissue samples were selected after histological analysis and classified according to World Health Organization recommendations (Table 1) . 20 Normal contralateral thyroid tissues were obtained from patients with a unifocal tumor. All specimens were frozen at Ϫ80°C in isopentane and stored in liquid nitrogen directly after surgical resection and until RNA extraction. Informed consent was obtained from all patients. Twentythree of these 65 samples were used for microarray experiments. All thyroid samples were obtained in euthyroid subjects, as assessed by serum thyroid stimulating hormone (TSH) concentrations in the normal range at the time of surgery. Complete clinical and histological information concerning samples used in this study is available in supplementary Table S1 (http://ajp.amjpathol.org).
Total RNA Preparation and Reverse Transcription
Total RNA was isolated from frozen tissue samples using Trireagent (Sigma-Aldrich, Saint Louis, MO) and purified on Rneasy columns (Qiagen, Hilden, Germany) according to manufacturer's protocols. Quality of RNA preparation, based on the 28S/18S ribosomal RNAs ratio, was assessed using the RNA 6000 Nano Lab-On-chip as developed on the Agilent 2100 Bioanalyzer device (Agilent Technologies, Palo Alto, CA). All specimens included in this study displayed a ratio of 28S to 18S higher than 1.5 (average 1.8). RNA samples were frozen in nucleasefree water (Promega Corporation, Madison, WI). One microgram of total RNA was reverse-transcribed by Moloney murine leukemia virus reverse transcriptase in the presence of random primers (Applied Biosystems, Foster City, CA). For each sample, the PAX8-PPAR␥1 translocation detection assay was performed as previously described. 18 Briefly, the PCR reaction was performed with several primers previously described.
6,7 PCR products were visualized using 2% agarose gel. For each sample with detectable PCR product, all visible bands were purified and directly sequenced to confirm the presence of PAX8-PPAR␥1 translocation. The efficiency of reverse transcription was controlled with amplification of several genes with the same cDNA (with quantitative real-time PCR).
Microarray Analysis
A pool composed by equal amount of total RNA from each tissue sample was used as the RNA reference. Five-microgram aliquots of total RNA from each sample and from the reference pool were used to generate labeled antisense cRNA with T7 RNA polymerase. Labeling of cRNAs was performed with cyanine 3 (Cy3)-CTP for all samples and cyanine 5 (Cy5)-CTP for the RNA reference (Perkin Elmer NEN, Boston, MA). Reverse transcription, linear amplification, cRNA labeling, and purification were performed using the Agilent Linear amplification kit. The cRNA concentration and Cy3-CTP or Cy5-CTP incorporation were assessed using an UV-visible spectrophotometer. We used custom-designed 60-mer oligonucleotide microarrays of 22,000 features, representing 16,840 known unique genes developed by Agilent Technologies. Hybridization was performed during 17 hours at 60°C, with 1 g of Cy3-labeled cRNA of each sample mixed to the same amount of Cy5-labeled cRNA reference.
The Feature Extraction software (Agilent Technologies) was used to quantify intensity of fluorescent images and to normalize results using the local background subtrac- 
Statistical Analysis
Microarray data analysis was performed using the Resolver software (Rosetta Inpharmatics, Kirkland, WA). All data were filtered to eliminate low-intensity value under 200 arbitrary units for both colors, a threshold determined on the basis of the linearity test. Each selected gene had at least a twofold change, with a P value less than 1% in a minimum of four independent samples. Using this procedure, 1859 genes passed the filter. For the unsupervised clustering, a hierarchical agglomerative algorithm that pairs samples according to their similarity was used. Analysis of variance (ANOVA) was performed on the microarray data and on the Q RT-PCR data. For each individual gene, one-way ANOVA tests were performed to compare results obtained from normal tissues and FTCs and from FTCs presenting or not presenting the translocation. Two-way ANOVA tests were applied for the Q RT-PCR data to compare average gene expression values between FTCs with and without the translocation while adjusting for the histological type.
Analysis of Promoter Sequences
To search potential peroxisome proliferator response element (PPRE) sequences within the upstream 2-kb sequence located before the coding determining sequence of the selected genes, a homology matrix was designed on the basis of nine well-characterized PPRE sequences of the human PPAR␥ promoter, including those regulating acyl-coenzyme A oxidase, apolipoprotein C-III, carnitine palmitoyltransferase 1B, ATP-binding cassette D2 (2 PPRE), aquaporin (AQ7), nuclear receptor LXR, and acylcoA binding protein genes. The homology matrix associates a value to each nucleotide at each position of the consensus PPRE (AGGTCA N AGGTCA) sequence. This value is related to the frequency of each nucleotide in the nine PPRE analyzed, and when the frequency is null, a negative value is associated. A score between Ϫ7 and 98 was attributed to each sequence analyzed. The threshold value for this score was determined as the minimum value of the 95% confidence interval of average of score obtained by the nine well-characterized PPRE. The number of putative promoters found in our gene set was compared with the number of putative PPRE expected by chance and determined in 500 randomly selected gene sets. More information is available in supplementary Table S3 (http://ajp.amjpathol.org).
Real-Time Quantitative PCR
Oligonucleotide primers and Taqman probes specific for PPAR␥, PAX8A, FGD3, decorin (DCN), RPLP0, PPIA, or 28S were designed to be intron spanning using the PrimerExpress computer software (Applied Biosystems). Sequences were from the GenBank database, and the oligonucleotides were purchased from MWG Biotech (Courtaboeuf, France). Primers and probes for thyroidspecific genes SLC5A5, TPO, and TG were already published; 21 and 18S, ANGPTL4, acetyl-Coenzyme A acyltransferase 1 (ACAA1), PDE8, and HBP17 were obtained from Assays-On-Demand (Applied Biosystems). Q-PCRs were performed on equivalent of 10 ng per total RNA per tube in a final volume of 18 l and developed as previously described. 18 The reference pool, corresponding to the microarray RNA reference, was used as a calibrator (1ϫ sample). Normalization was assessed by a combination of four housekeeping genes (18S, 28S, RPL0, and PPIA). 22 
Immunohistochemistry and Tissue Array Construction
A tissue array, including all of the samples analyzed in the microarray experiment, was constructed using a tissue-arrayer device (Alphelys, Plaisir, France) with a 1-mm needle. Quadruplicate samples were prepared both from the tumor part and from the normal thyroid tissue at distance from the tumor. A total of 128 spots by antibody were analyzed.
Immunohistochemistry was performed on formalinfixed paraffin-embedded 5-m sections as described previously. 18 Two independent observers carried out the immunohistochemical analysis, considering both the percentage of positive cells (noted as percentage of stained cells) and the intensity of staining (noted from 0 to 4 ϩ). Antibody against PPAR␥ was a mouse monoclonal antibody ␥, which recognizes the COOH terminus of the protein (Santa Cruz, CA). A 26-amino acid peptide and a 22-amino acid peptide, spanning the COOH-terminal portions of ACAA1 and FGD3, respectively, were synthesized by a conventional solid-phase method using a model 432A peptide synthesizer (Applied Biosystems). The identity and purity of each peptide were verified by 1) amino acid analysis on an ␣ LKB analyzer (LKB, Rockville, MD); 2) HPLC; and 3) sequence analysis using ES-TOF mass spectrometry (Micromass Quattro LCT, Villeurbanne, France). The peptides were then conjugated to keyhole limpet hemocyanin using benzidine as the coupling agent, and two rabbits were immunized by intradermal injections of each synthetic peptide-carrier conjugate. After three subsequent boosts at 3-week intervals, animals were bled, and their sera were tested in an enzyme-linked immunosorbent assay.
Results
Detection of the PAX8-PPAR␥1 Translocation
The PAX8-PPAR␥1 rearrangement was detected in 4 of 23 (17%) FTCs and 1 of 16 (6%) benign hypofunctioning follicular adenomas (FTAs), as previously described. 18 In the five positive samples, RT-PCR and sequencing revealed four isoforms generated by the fusion of different exons of PAX8 (exon 7; exons 7 and 8; exons 7, 8, and 9; and exons 7 and 9) with exon 1 of PPAR␥1. None of the normal thyroid tissues (n ϭ 17), Hü rthle-cell carcinomas (n ϭ 4), and anaplastic carcinomas (n ϭ 5) displayed any evidence of the translocation.
Analysis and Differential Gene Expression
Microarray experiments, based on the dual-color technology were performed on 23 thyroid samples, including 8 FTCs, 4 FTAs, and 11 normal contralateral tissues. Three FTCs and one FTA harbored PAX8-PPAR␥1 rearrangement. Using the Resolver software, an intensityand fold changed-based filtering approach selected 1859 features from the 22,000 present on the 60-mer oligonucleotides microarray for further analysis. The nonsupervised hierarchical clustering performed on these features is presented as a hyperbolic view in Figure 1 . One cluster included 8 of 11 normal thyroid tissue samples. Two normal contralateral tissues (NT6 and NT9), presenting lymphocytic infiltration at histological examination, segregated separately and were associated with the presence of serum anti-thyroid antibodies. Most FTAs and FTCs clustered together. One carcinoma sample, namely FTC17, displayed a quite different expression profile compared with those of the FTCs and corresponded to a particularly aggressive tumor. Interestingly, a peculiar cluster contained all of the four PAX8-PPAR␥-positive tumors. This distinct cluster underlines the existence of a specific gene expression profile associated with the translocation.
Gene Expression Profile Associated with Follicular Thyroid Carcinomas
To explore gene expression profiles related to tumors, an ANOVA test was performed for each of the 1859 filtered genes. Normal thyroid tissues displayed 61 genes differentially expressed at P Ͻ 0.01 (N/TϪ set) when compared with PAX8-PPAR␥-negative FTCs and 116 genes when compared with PAX8-PPAR␥-positive FTCs at P Ͻ 0.01 (N/Tϩ set). These sets of genes are described in supplementary Table S2 (http://ajp.amjpathol.org). Only 27 genes were differently regulated in both sets of FTCs versus normal tissues (Figure 2) . Some of these genes were already found to be up-regulated in human FTCs, such as transforming growth factor ␣ (TGFA), or downregulated, such as gelsolin, tumor necrosis factor receptor superfamily, member 11b, or trefoil factor 3. 23 Interestingly, increased creatine kinase, mitochondrial 1 and decreased DCN gene expressions were also reported in a murine model of follicular carcinoma. 24 The low number of genes in common between those two sets might indicate separate oncogenesis pathways. When genes were ordered by ontology, N/TϪ and N/Tϩ gene sets displayed important differences (Figure 2 ). Microarray analysis revealed that the N/TϪ set mainly included down-regulated genes (84%) as previously described. 25 This included genes involved in cell signaling (CRABP1, DDR2, and DPP6), immunity (CCL21, CXCL12, and DF), cellular metabolism, and enzymes (FGL2 and PGM5). Interestingly, the N/Tϩ set mainly included upregulated genes (76%) such as genes involved in cellular energetic metabolism (ACAA1, AK3L1, fructose(1,6) bisphosphatase (FBP1), DGAT2, and AQ7), cell signaling (GDF5, RDC1, DPP4, and FGD3), cellular growth (GADD45G, MYCL1, and TNFRSF21), and transcription (NFE2L3 and PPAR␥). Surprisingly, the statistical analysis did not select the thyroid-specific genes present on the microarray, including NIS, TPO, TG, TSH-R, and DUOX2, as differently expressed between FTCs and normal tissue samples.
Gene Expression Profile Associated with the PAX8-PPAR␥ Translocation
To further investigate the expression profile associated with the PAX8-PPAR␥-rearrangement, we compared these two groups of follicular tumors by the ANOVA test (P Ͻ 0.01). A set of 93 genes (TϪ/Tϩ set) was identified ( Figure 3 ; supplementary Table S2 (http://ajp.amjpathol.org)). Interestingly, a 26-fold up-regulated PPAR␥ gene expression was detected in the positive follicular tumors. Because the entire PPAR␥1 open reading frame is present in the rearranged product, wild-type PPAR␥ and PAX8-PPAR␥ transcripts were undistinguishable by the corresponding 60-mer oligonucleotide. In accordance with previous results, PPAR␥ expression level appears to be the most specific difference between those two tumor groups. 8, 16, 18 Several genes, known as PPAR␥ positively regulated targets, were up-regulated in PAX8-PPAR␥-positive tumors, including angiopoietin-like 4 and aquaporin 7, which displayed a 23-fold and 4-fold gene expression increase, respectively. Expression of genes involved in cellular metabolism, particularly those associated to lipid, glucose, and amino acid metabolisms, was modified: ACAA1, a gene involved in the ␤-oxidation process; DGAT2, an acyl CoA diacylglycerol acyltransferase; and FBP1, involved in neo-glucogenesis, were increased by a fourfold, eightfold, and sevenfold, respectively. Several genes associated to tumorigenesis, such as MYCL1 (homolog to v-myc), TGFA, and neuregulin 1, and to cell signaling, such as FGD3, a putative guanine nucleotide exchange factor, were also up-regulated. Endothelial cell-specific molecule 1 (ESM1), placental growth factor (PGF), and HBP17 (heparin-binding growth factor binding protein also name FGF-BP1), all genes known to activate angiogenesis, displayed increased gene expression. Metallothionein MT1G and MT1H, overexpressed in several types of carcinomas, were increased by 14-fold and 7-fold, respectively. Finally, several genes with unknown function (FLJ11154, FLJ20489, and FLJ41259) were up-regulated more than ninefold.
Analysis of Gene Promoter Sequences
We first examined whether any variation of gene expression could be related to its chromosomal localization. The selected genes spread all over the genome, and no significant association between their position and their expression was found (data not shown). The in silico analysis of the promoter of the selected genes indicated that putative PPRE were detectable in 68 promoters of the 93 genes in TϪ/Tϩ set (73%). Among genes with putative PPRE, we also observed genes already proposed to be regulated by PPAR␥ such as ANGPTL4, AQ7, ACAA1, APOA1, or FGD3. The frequency of putative PPRE in Tϩ/TϪ set was significantly higher than expected by chance (P value Ͻ0.001). All PPRE sequences are reported in the supplementary Table S3 (http://ajp.amjpathol.org). 
Quantitative Gene Expression Analysis
Q RT-PCR was carried out to confirm changes in the expression of 15 selected genes on a larger series of 65 thyroid tumor samples, including the 23 samples analyzed in the microarray experiments. Five tumors harbored the PAX8-PPAR␥1 rearrangement (four FTCs and one FTA). The values were normalized using the mean of the four housekeeping genes (18S, 28S, RPLP0, and PPIA) 22 and compared with the pool of all samples. First, we compared the expression values in the 23 samples tested both by Q RT-PCR and by microarray experiments. A significant correlation of all genes tested was observed (P Ͻ 0.01). Second, analysis of thyroid-specific genes TG, TPO, and NIS/SLC5A5 indicated that they were expressed in all tissues excepted in anaplastic carcinomas. Although they were not retained by the microarray analysis, their expression was significantly down-regulated in follicular carcinomas compared with normal tissue (P Ͻ 0.05, P Ͻ 0.01, and P Ͻ 0.001, respectively), as previously described. 21 NIS/SLC5A5 and TPO also appeared to be slightly decreased in FTCs compared with FTAs (P Ͻ 0.05 and P Ͻ 0.01). However, their expression was not significantly different between tumors harboring or not the translocation.
Third, 12 genes selected from microarray analysis were analyzed by Q RT-PCR in a large series of thyroid tumors (Figure 4) . The ANOVA was adjusted both for the tumor type (FTA or FTC) and for the presence or absence of the translocation. In tumors positive for the translocation when compared with negative tumors, Q RT-PCR analysis clearly confirmed the overexpression of PPAR␥, ANGPTL4, ACAA1, HBP17, and FGD3 genes (P Ͻ 0.001) and TGFA (P ϭ 0.003). No significant changes between gene expression of positive and negative tumors for translocation were found for PAX8A (P ϭ 0.084), PDE8B (P ϭ 0.088), and ESM1 (P ϭ 0.092). The expression was significantly different between FTAs and FTCs only for CRAPB1 gene (P Ͻ 0.002). Finally, TGFA (P ϭ 0.001), PDE8B (P ϭ 0.03), CRABP1 (P Ͻ 0.001), ESM1 (P Ͻ 0.001), and DCN (P Ͻ 0.001) gene expression was significantly decreased in both follicular benign and malignant tumors when compared with normal thyroid tissues.
Immunohistochemistry
Tissue array allowed the immunohistochemistry of all normal, benign, and malignant thyroid tissue specimens tested in microarray experiments. Using PPAR␥ antibody, a strong immunostaining was found in nuclei of all tumors displaying the PAX8-PPAR␥1 translocation ( Figure 5, A  and B) . Using the anti-ACAA1 antibody, a strong immunostaining was observed in the cytoplasm of tumor cells presenting the PAX8-PPAR␥1 translocation. The staining showed a characteristic localization, consisting in small or large intracytoplasmic positive vacuoles. Large positive vacuoles were preferentially located in the apical part of tumor cells ( Figure 5, C and D) . In normal thyroid tissue, a weak staining was observed in a minority of cells with a lower number of vacuoles. Immunohistochemistry with the anti-FGD3 antibody indicated that the FGD3 protein was heterogeneously distributed in the tumor. In tumors with the rearrangement, a more intense staining was observed; FGD3 was localized at the lateral membrane without any staining at the basal or apical membranes ( Figure 5 , E and F).
Discussion
Identifying molecular genetic mechanisms is particularly challenging in thyroid oncogenesis because differentiated thyroid tumors present with distinct benign and malignant histotypes with different behaviors. Only a few large-scale genomics studies have been devoted to follicular tumors. 23, 26 In the present study, we have undertaken expression profiling of FTCs that appear as histologically homogeneous and do or do not harbor the PAX8-PPAR␥1 rearrangement.
Nonsupervised hierarchical clustering performed on results obtained for FTAs and FTCs was not efficient to distinguish benign and malignant tumoral tissues, probably because of the low number of samples included in the analysis. However, statistical analysis revealed distinct patterns between normal tissues and follicular tumors. Those sets of genes included several interesting genes such as SELE, CRABP1, gelsolin, DCN, or PPAR␥ that have been previously identified during thyroid tumor progression in a mouse model and in human tu- mors. 17, 24, 25 The small leucine-rich proteoglycan decorin is associated with negative regulation of cell growth and has a prominent role in TGF-␤ and EGFR activation pathways that contribute to its role in cellular proliferation, angiogenesis, and immunomodulation. 24, 27 The expression of thyroid-specific genes, such as TG, TPO, TSH-R, or NIS, was detectable in the microarray experiments and by quantitative PCR. None of them appeared to be dif- Figure 5 . PPAR␥, ACAA1, and FGD3 immunostaining in thyroid carcinomas presenting the PAX8-PPAR␥ translocation. PPAR␥ immunostaining is presented at magnification ϫ100 (A) and ϫ200 (B). A strong positivity is observed in the nuclei of tumor cells (long arrows). Nuclei of endothelial cells are not stained (small arrows). For ACAA1 immunostaining at magnification ϫ100 (C), numerous positive intracytoplasmic vacuoles are observed in the majority of tumor cells. For ACAA1 immunostaining at magnification ϫ400 (D), positive large vacuoles are present in the apical part of tumor cells (long arrows); smaller vacuoles are indicated by small arrows (L, lumen of tumor follicle). FGD3 immunostaining is presented at magnification ϫ100 (E) and ϫ400 (F). Heterogeneity of the staining is observed in the tumor follicle. FGD3 localizes at the lateral membrane (long arrows), and no staining is observed at basal or apical membrane in translocated tumors.
ferentially regulated between tumors harboring or not harboring the translocation.
Overall, in the FTC signature, a peculiar group including all of the PAX8-PPAR␥1-positive tumors clustered separately. Several lines of evidence indicate that angiogenic factors are involved in neoplastic growth and aggressiveness of thyroid tumors. Vascular endothelial growth factor (VEGF), VEGF-C, and angiopoietin-2 and their tyrosine kinase receptors are overexpressed in thyroid carcinomas. 28 Follicular carcinomas with PPAR␥ rearrangement exhibited vascular invasion. 29 In our study, increased gene expression of ESM1, PGF, and HBP17 is consistent with the overexpression of ANGPTL4 or with the down-regulation of tissue inhibitor of metalloproteinase 3 (TIMP3). ESM1, a proteoglycan secreted by endothelial cells under the control of inflammatory cytokines, plays a role in the adhesion process and angiogenesis. 30, 31 Both PGF and TIMP3 regulate inter-and intramolecular cross-talks between the VEGF receptor tyrosine kinases, and TIMP3 inhibits downstream signaling and angiogenesis independently of its MMP-inhibitory activity. Although the function of ANGPTL4 is not completely understood, it is known to promote angiogenesis in response to hypoxia. 32 In solid tumors, functional properties of only a few fusion genes have been characterized. [33] [34] [35] Recently, it was demonstrated that the transforming properties of the PAX8-PPAR␥1 fusion oncoprotein depend in part on the inhibition of wild-type PPAR␥. 19 This is in line with the down-regulation of PPAR␥ expression in several tumors not harboring the PAX8-PPAR␥ translocation, including thyroid cancers. 17 In our study, the finding of an upregulation of the expression of several known or suspected PPAR␥ target genes leads to question the assumed mechanism of action of the chimeric product as having a dominant-negative effect. ANGPTL4, which is positively regulated by PPAR␥ agonist, was found to be one of the most up-regulated in PAX8-PPAR␥ FTCs. Aquaporin 7, involved in water channel activity, was also detected as up-regulated in a recent report. 36 Expression of multiple genes involved in lipid (ACAA1), glucose (FBP1), and amino acid metabolisms was increased in tumors presenting the translocation in line with recent results. (During the reviewing of this paper, Lui et al 37 described a molecular clustering associated with the PAX8-PPAR␥ translocation. ACAA1(AF035295), PPARG(L40904), FBP1(U21931), ABCC3(AF085692), FBN1(X63556), and ATP10B(AB018258) are shared in the two studies.) Furthermore, putative PPRE were detectable in promoter sequences of these genes, suggesting that their expression could be directly regulated by PPAR␥. Finally, among genes with putative assigned function, the increased expression of FGD3 gene, a recently discovered member of the FGD1 family, 38 deserves further investigation into its potential role in the oncogenic process associated with the PAX8-PPAR␥1 rearrangement. FGD1 encodes a guanine nucleotide exchange factor (GEF) that specifically activates the Rho GTPase Cdc42, and interacts with cortactin in Arp2/3 complex-mediated actin assembly. 39 Like RAS, Rho GTPases serve similar functions in signal transduction and for the establishment of cadherin-dependent cell-cell contact, and aberrant GTPase function has been implicated in cancer development. 40, 41 In summary, we report, for the first time, a global gene expression analysis of follicular thyroid carcinomas bearing the PAX8-PPAR␥1 translocation using Agilent oligonucleotide microarrays, quantitative RT-PCR, and immunohistochemistry on tissue microarrays. The specific pattern associated with the PPAR␥ rearrangement is in line with previous hypotheses suggesting an independent pathway. 10 Moreover, the differentially expressed genes would be of value both for discovering new potential targets of PPAR␥ and for identifying molecular pathways involved in the development of thyroid carcinomas.
